zinc supplementation and non-alcoholic fatty liver disease

Effect of Zinc Supplementation and dietary weight loss on oxidative stress, steatosis, liver enzymes, glycemic and lipid profile Status in Non-Alcoholic Fatty Liver disease

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181005041238N1

Enrollment

Registered

2018-12-13

Start date

2018-10-23

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver.

Interventions

Intervention 1: Intervention group: weight loss diet and zinc gluconate(30 mg elemental-Dine) for 3 months in non-alcoholic fatty liver disease. Intervention 2: Control group: weight loss diet and pla

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients aged up to 18 years and more an involvement of 33% of liver tissue with fats by ultrasound BMI between 25-35

Exclusion criteria

Exclusion criteria: An unwillingness of patients to participate in the study pregnancy breastfeeding travel for more than 2 weeks smokers iron supplementation users diabetes patients alcohol consumption patients with hepatitis B and C hemochromatosis Wilson's disease patients with heart failure kidney disease autoimmunity hypothyroidism or hyperthyroidism Grade3 fatty liver patients athletes patients with any malabsorption Weight changes over 5 kg In the last 3 months follow a diet plan and certain physical activity use of hepatotoxic drugs such as blockers, calcium channel, high doses of synthetic estrogens, methotrexate, chloroquine, tamoxifen, non-steroid anti-inflammatory drugs, amiodarone, statins and fibers consumption drugs such as cefalexin, tetracycline and its derivatives, ceftibuten, deferiprone, antibiotics Quinolone is consumed

Design outcomes

Primary

Measure	Time frame
Differences of serum AST enzyme. Timepoint: Before the intervention begins and Week 12. Method of measurement: kit.;Differences of serum ALP. Timepoint: Before the intervention begins and Week 12. Method of measurement: kit.;Differences of serum SOD1 enzyme. Timepoint: Before the intervention begins and Week 12. Method of measurement: colorimetry.;Differences of serum MDA. Timepoint: Before the intervention begins and Week 12. Method of measurement: colorimetry.;Differences of serum insulin. Timepoint: Before the intervention begins and week12. Method of measurement: kit.;Differences of fasting blood sugar. Timepoint: Before the intervention begins and Week 12. Method of measurement: kit.;Differences of serum triglyceride. Timepoint: Before the intervention begins and Week 12. Method of measurement: kit.;Differences of serum LDL-C. Timepoint: Before the intervention begins and Week 12. Method of measurement: kit.;Differences of serum HDL-C. Timepoint: Before the intervention begins and Week 12. Method of measurement: kit.;Differences of serum total cholesterol. Timepoint: Before the intervention begins and Week 12. Method of measurement: kit.;Differences of serum ALT enzyme. Timepoint: Before the intervention begins and Week 12. Method of measurement: kit.	—

Measure

Time frame

Differences of serum AST enzyme. Timepoint: Before the intervention begins and Week 12. Method of measurement: kit.;Differences of serum ALP. Timepoint: Before the intervention begins and Week 12. Method of measurement: kit.;Differences of serum SOD1 enzyme. Timepoint: Before the intervention begins and Week 12. Method of measurement: colorimetry.;Differences of serum MDA. Timepoint: Before the intervention begins and Week 12. Method of measurement: colorimetry.;Differences of serum insulin. Timepoint: Before the intervention begins and week12. Method of measurement: kit.;Differences of fasting blood sugar. Timepoint: Before the intervention begins and Week 12. Method of measurement: kit.;Differences of serum triglyceride. Timepoint: Before the intervention begins and Week 12. Method of measurement: kit.;Differences of serum LDL-C. Timepoint: Before the intervention begins and Week 12. Method of measurement: kit.;Differences of serum HDL-C. Timepoint: Before the intervention begins and Week 12. Method of measurement: kit.;Differences of serum total cholesterol. Timepoint: Before the intervention begins and Week 12. Method of measurement: kit.;Differences of serum ALT enzyme. Timepoint: Before the intervention begins and Week 12. Method of measurement: kit.

—

Secondary

Measure	Time frame
Differences of BMI. Timepoint: Before the intervention begins and week6 and week12. Method of measurement: Weighing scales and meter.;Differences of body fat percentage. Timepoint: Before the intervention begins and week6 and week12. Method of measurement: body stat.;Differences of waist circumference. Timepoint: Before the intervention begins and week6 and week12. Method of measurement: meter.;Differences of Hip circumference. Timepoint: Before the intervention begins and week6 and week12. Method of measurement: meter.	—

Measure

Time frame

Differences of BMI. Timepoint: Before the intervention begins and week6 and week12. Method of measurement: Weighing scales and meter.;Differences of body fat percentage. Timepoint: Before the intervention begins and week6 and week12. Method of measurement: body stat.;Differences of waist circumference. Timepoint: Before the intervention begins and week6 and week12. Method of measurement: meter.;Differences of Hip circumference. Timepoint: Before the intervention begins and week6 and week12. Method of measurement: meter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojdeh Fathi

Esfahan University of Medical Sciences

mojdeh68.fathi@yahoo.com+98 61 3337 5155

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026